The objective of this study is to address this research gap by assessing the association between SGLT2 inhibitor use and AF risk in a nationally representative sample of T2D patients in the United States and determine any effect variation across sex, race/ethnicity, and baseline comorbidities. Here, SLC5A2 is linked to atrial fibrillation.